Latest International Markets News

Lovisa Holdings reveals robust growth with 44 net new stores and a 26.2% rise in global sales during the first 20 weeks of FY26, signaling strong momentum ahead of its Annual General Meeting.

Bubs Australia Limited reported a solid FY25 with $102.5 million revenue and outlined ambitious FY26 guidance targeting up to $125 million, driven by overseas markets and strategic investments.

Spacetalk Ltd reveals a successful pivot to a software-led, hardware-enabled model, reporting 12% revenue growth and expanding into 15 international markets. The company targets $20–25 million in recurring revenue for 2026, underpinned by new product launches and strategic telco partnerships.

Orthocell Limited reports growing adoption of its Remplir™ nerve repair product in nerve-sparing prostate cancer surgeries across Australia, positioning for a significant U.S. market expansion. The company is investing in research and commercial infrastructure ahead of a medium-term U.S. launch.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

AFT Pharmaceuticals has reported a robust first half of FY26, posting a 33% revenue increase to a record $114.9 million and returning to profitability amid strong growth in Australia and international markets. The company’s advancing R&D pipeline and strategic licensing deals position it well for ambitious FY27 targets.

Urbanise.com Limited has secured a landmark partnership with National Australia Bank to integrate banking services into its cloud-based strata management platform, marking a pivotal step in modernising an industry long reliant on legacy systems.

Zeotech Limited has signed a non-binding Letter of Intent with Bisley & Company to explore marketing and distribution of its high-reactivity metakaolin product, AusPozz™, across Australia and key international markets.

Paradigm Biopharmaceuticals has drawn down US$5 million under its convertible note facility to fund the accelerated expansion of its global Phase 3 trial for knee osteoarthritis treatment.

Airtasker Limited has announced a $10 million equity capital raise to accelerate marketing efforts in the UK and US, following a strong first quarter with group revenue up 20.5% year-on-year. Strategic partnerships, including a cornerstone investment from iHeartMedia, underpin its international growth ambitions.

Airtasker has raised $10 million in a strategic equity placement led by iHeartMedia, aiming to accelerate its growth in the US and UK markets through targeted marketing and expanded media partnerships.

Bioxyne Limited is expanding its footprint with a new UK GMP-certified medicinal cannabis manufacturing site, backed by £850,000 in funding from South of Scotland Enterprise. This move positions the company to tap into the UK’s growing medicinal cannabis market, the second largest in Europe.